Overview

• Tecelra is the first gene therapy approved in the U.S. that uses a patient's own T-cells to target cancer.
• The therapy, priced at $727,000, received accelerated approval and requires further confirmatory trials.
• Synovial sarcoma affects about 1,000 people annually in the U.S., primarily young adults.
• In clinical trials, Tecelra showed a 43.2% response rate among participants, with effects lasting an average of six months.
• The treatment carries a risk of severe cytokine release syndrome, a dangerous immune response.